{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:55:06Z","timestamp":1793994906386,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-022-03295-2","type":"journal-article","created":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T23:11:01Z","timestamp":1673219461000},"page":"134-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-4576","authenticated-orcid":false,"given":"Fernanda","family":"Bueno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6497-315X","authenticated-orcid":false,"given":"Anabella","family":"Smulever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7450-5832","authenticated-orcid":false,"given":"In\u00e9s","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgelina","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Del Grecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manglio","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejo","family":"Lingua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Voogd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Carmen","family":"Negueruela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5217-3294","authenticated-orcid":false,"given":"Erika","family":"Abelleira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-7085","authenticated-orcid":false,"given":"Fabian","family":"Pitoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"3295_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ecl.2008.02.003","volume":"37","author":"RL Neff","year":"2008","unstructured":"R.L. Neff, W.B. Farrar, R.T. Kloos, B.D. Kenneth, Anaplastic thyroid carcinoma. Endocrinol. Metab. Clin. North Am. 37, 525\u2013538 (2008)","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"3295_CR2","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1158\/1078-0432.CCR-11-1155","volume":"17","author":"LM Caronia","year":"2011","unstructured":"L.M. Caronia, J.E. Phay, M.H. Shah, Role of BRAF in thyroid oncogenesis. Clin. Cancer Res 17, 7511\u20137517 (2011)","journal-title":"Clin. Cancer Res"},{"key":"3295_CR3","doi-asserted-by":"publisher","unstructured":"S. Saini, K. Tulla, A.V. Maker, K.D. Burman, B.S. Prabhakar, Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol Cancer. (2018). https:\/\/doi.org\/10.1186\/s12943-018-0903-0.","DOI":"10.1186\/s12943-018-0903-0"},{"key":"3295_CR4","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/cncr.20936","volume":"103","author":"E Kebebew","year":"2005","unstructured":"E. Kebebew, F.S. Greenspan, O.H. Clark, K.A. Woeber, A. McMillan, Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103, 1330\u20131335 (2005)","journal-title":"Cancer"},{"key":"3295_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1245\/aso.2002.9.1.57","volume":"9","author":"JP Pierie","year":"2022","unstructured":"J.P. Pierie, A. Muzikansky, R.D. Gaz, W.C. Faquin, M.J. Ott, The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann. Surg. Oncol. 9, 57\u201364 (2022)","journal-title":"Ann. Surg. Oncol."},{"key":"3295_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nrendo.2017.76","volume":"13","author":"E Molinaro","year":"2017","unstructured":"E. Molinaro, C. Romei, A. Biagini, E. Sabini, L. Agate, S. Mazzeo, G. Materazza, S. Sellari-franceschini, A. Ribechini, L. Torregrossa, F. Basolo, P. Vitti, R. Elisei, Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat. Rev. Endocrinol. 13, 644\u2013660 (2017)","journal-title":"Nat. Rev. Endocrinol."},{"key":"3295_CR7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1023\/A:1008322002520","volume":"11","author":"D Giuffrida","year":"2000","unstructured":"D. Giuffrida, H. Gharib, Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann. Oncol. 11, 1083\u20131089 (2000)","journal-title":"Ann. Oncol."},{"key":"3295_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1089\/thy.2012.0252","volume":"23","author":"N Besic","year":"2013","unstructured":"N. Besic, B. Gazic, Sites of metastases of anaplastic thyroid carcinoma: autopsy findings in 45 cases from a single institution. Thyroid 23, 709\u2013713 (2013)","journal-title":"Thyroid"},{"key":"3295_CR9","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"S. Filetti, C. Durante, D. Hartl, S. Leboulleux, L.D. Locati, K. Newbold, M.G. Papotti, A. Berruti, ESMO Guidelines Committee: Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 1856\u20131883 (2019)","journal-title":"Ann. Oncol."},{"key":"3295_CR10","doi-asserted-by":"publisher","unstructured":"M. Ragazzi, A. Ciarrocchi, V. Sancisi, G. Gandolfi, A. Bisagni, S. Piana, Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol. (2014). https:\/\/doi.org\/10.1155\/2014\/790834.","DOI":"10.1155\/2014\/790834"},{"key":"3295_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"K.C. Bible, E. Kebebew, J. Brierley, J.P. Brito, M.E. Cabanillas, T.J. Clark Jr., A. Di Cristofano, R. Foote, T. Giordano, J. Kasperbauer, K. Newbold, Y.E. Nikiforov, G. Randolph, M.S. Rosenthal, A.M. Sawka, M. Shah, A. Shaha, R. Smallridge, C.K. Wong-Clark, 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid 31, 337\u2013386 (2021)","journal-title":"Thyroid"},{"key":"3295_CR12","doi-asserted-by":"publisher","first-page":"E2083","DOI":"10.1002\/hed.24384","volume":"38","author":"SM Glaser","year":"2016","unstructured":"S.M. Glaser, S.F. Mandish, B.S. Gill, G.K. Balasubramani, D.A. Clump, S. Beriwal, Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival. Head. Neck 38, E2083\u2013E2090 (2016)","journal-title":"Head. Neck"},{"key":"3295_CR13","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1200\/JCO.20.03093","volume":"39","author":"LJ Wirth","year":"2021","unstructured":"L.J. Wirth, M.S. Brose, E.J. Sherman, L. Licitra, M. Schlumbeger, S.I. Sherman, K.C. Bible, B. Robinson, P. Rodien, Y. Godbert, C. De La Fouchardiere, K. Newbold, C. Nutting, S. Misir, R. Xie, A. Almonte, W. Ye, M.E. Cabanillas, Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients with Anaplastic Thyroid Cancer. J. Clin. Oncol. 39, 2359\u20132366 (2021)","journal-title":"J. Clin. Oncol."},{"key":"3295_CR14","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/hmg\/ddu749","volume":"24","author":"JW Kunstman","year":"2015","unstructured":"J.W. Kunstman, C.C. Juhlin, G. Goh, T.C. Brown, A. Stenman, J.M. Healy, J.C. Rubinstein, M. Choi, N. Kiss, C. Nelson-Williams, S. Mane, D.L. Rimm, M.L. Prasad, A. Hoog, J. Zedenius, C. Larsson, R. Korah, R.P. Lifton, T. Carling, Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum. Mol. Genet. 24, 2318\u20132329 (2015)","journal-title":"Hum. Mol. Genet."},{"key":"3295_CR15","doi-asserted-by":"publisher","unstructured":"A. Guerra, V. Di Crescenzo, A. Garzi, M. Cinelli, C. Carlomagno, M. Tonacchera, P. Zeppa, M. Vitale, Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review. BMC Surg. (2013). https:\/\/doi.org\/10.1186\/1471-2482-13-S2-S44.","DOI":"10.1186\/1471-2482-13-S2-S44"},{"key":"3295_CR16","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"I. Landa, T. Ibrahimpasic, L. Boucai, R. Sinha, J.A. Knauf, R.H. Shah, S. Dogan, J.C. Ricarte-Filho, G.P. Krishnamoorthy, B. Xu, N. Schutlz, M.F. Berger, C. Sander, S.B. Taylor, R. Ghossein, I. Gangly, J.A. Fagin, Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Invest 126, 1052\u20131066 (2016)","journal-title":"J. Clin. Invest"},{"key":"3295_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/thy.2016.0076","volume":"27","author":"VC Sandulache","year":"2017","unstructured":"V.C. Sandulache, M.D. Williams, S.Y. Lai, C. Lu, W.N. William, N.L. Busaidy, G.J. Cote, R.R. Singh, R. Luthra, M.E. Cabanillas, Real-time genomic characterization utilizing circulating cell-free DNA in patients with anaplastic thyroid carcinoma. Thyroid 27, 81\u201387 (2017)","journal-title":"Thyroid"},{"key":"3295_CR18","doi-asserted-by":"publisher","first-page":"626","DOI":"10.2174\/138920211798120808","volume":"12","author":"A Antonelli","year":"2011","unstructured":"A. Antonelli, P. Fallahi, S.M. Ferrari, I. Ruffilli, F. Santini, M. Minuto, D. Galleri, P. Miccoli, New targeted therapies for thyroid cancer. Curr. Genomics 12, 626\u2013631 (2011)","journal-title":"Curr. Genomics"},{"key":"3295_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.21037\/gs.2019.05.05","volume":"8","author":"A Antonelli","year":"2019","unstructured":"A. Antonelli, S.M. Ferrari, G. Elia, A. Patrizio, P. Fallahi, Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up. Gland Surg. 8, 298\u2013300 (2019)","journal-title":"Gland Surg."},{"key":"3295_CR20","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1089\/thy.2020.0086","volume":"30","author":"B Xu","year":"2020","unstructured":"B. Xu, T. Fuchs, S. Dogan, I. Landa, N. Katabi, J.A. Fagin, R.M. Tuttle, E. Sherman, A.J. Gill, R. Ghossein, Dissecting anaplastic thyroid carcinoma: A comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid 30, 1505\u20131517 (2020)","journal-title":"Thyroid"},{"key":"3295_CR21","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/cncr.21073","volume":"103","author":"RM Quiros","year":"2005","unstructured":"R.M. Quiros, H.G. Ding, P. Gattuso, R.A. Prinz, X. Xu, Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103, 2261\u20132268 (2005)","journal-title":"Cancer"},{"key":"3295_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"V. Subbiah, R.J. Kreitman, Z.A. Wainberg, J.Y. Cho, J.H.M. Schellens, J.C. Soria, P.Y. Wen, C. Zielinski, M.E. Cabanillas, G. Urbanowitz, B. Mookerjee, D. Wang, F. Rangwala, B. Keam, Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer. J. Clin. Oncol. 36, 7\u201313 (2018)","journal-title":"J. Clin. Oncol."},{"key":"3295_CR23","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1089\/thy.2020.0251","volume":"30","author":"A Smulever","year":"2020","unstructured":"A. Smulever, S. Barrio Lower Daniele, G. Damiano, F. Pitoia, Complete surgical resection after Dabrafenib plus Trametinib treatment in a patient with locally advanced and metastatic anaplastic thyroid carcinoma with a BRAF V600E mutation. Thyroid 30, 1224\u20131225 (2020)","journal-title":"Thyroid"},{"key":"3295_CR24","doi-asserted-by":"publisher","first-page":"e3490","DOI":"10.1210\/clinem\/dgaa421","volume":"105","author":"F Pitoia","year":"2020","unstructured":"F. Pitoia, A. Smulever, F. Jerkovich, Letter to the Editor: \u201cFoundation OneTM Genomic Interrogation of Thyroid Cancers in Patients with Metastatic Disease Requiring Systemic Therapy\u201d. J. Clin. Endocrinol. Metab. 105, e3490\u2013e3491 (2020)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3295_CR25","unstructured":"M.B. Amin, S. Edge, F. Greene, D.R. Byrd, R.K. Brookland, M.K. Washington, J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup, J.D. Brierley, L.E. Gaspar, R.L. Schilsky, C.M. Balch, D.P. Winchester, E.A. Asare, M. Madera, D.M. Gress, L.R. Meyer, AJCC Cancer Staging Manual, 8th edn. (2017)"},{"key":"3295_CR26","unstructured":"National Cancer Institute. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"3295_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, E.T. McFadden, P.P. Carbone, Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649\u2013655 (1982)","journal-title":"Am. J. Clin. Oncol."},{"key":"3295_CR28","first-page":"S96","volume":"53","author":"M Bell\u00f3","year":"2011","unstructured":"M. Bell\u00f3, V.M. Becerril-Montekio, The health system of Argentina. Salud Publica Mex. 53, S96\u2013S108 (2011)","journal-title":"Salud Publica Mex."},{"key":"3295_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1677\/ERC-08-0154","volume":"16","author":"RC Smallridge","year":"2009","unstructured":"R.C. Smallridge, L.A. Marlow, J.A. Copland, Anaplastic thyroid carcinoma: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 16, 17\u201344 (2009)","journal-title":"Endocr. Relat. Cancer"},{"key":"3295_CR30","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","volume":"22","author":"RC Smallridge","year":"2010","unstructured":"R.C. Smallridge, J.A. Copland, Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin. Oncol. (R. Coll. Radio.) 22, 486\u2013497 (2010)","journal-title":"Clin. Oncol. (R. Coll. Radio.)"},{"key":"3295_CR31","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1089\/thy.2014.0004","volume":"24","author":"E Brignardello","year":"2014","unstructured":"E. Brignardello, N. Palestini, F. Felicetti, A. Castiglione, A. Piovesan, M. Gallo, M. Freddi, U. Ricardi, G. Gasparri, G. Ciccone, E. Arvat, G. Bocuzzi, Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012. Thyroid 24, 1600\u20131606 (2014)","journal-title":"Thyroid"},{"key":"3295_CR32","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1210\/jc.2017-01180","volume":"102","author":"N Prasongsook","year":"2017","unstructured":"N. Prasongsook, A. Kumar, A.V. Chintakuntlawar, R.L. Foote, J. Kasperbauer, J. Molina, Y. Garces, D. Ma, M.A. Neben Wittich, J. Rubin, R. Richardson, J. Morris, I. Hay, V. Fatourechi, B. Mclver, M. Ryder, G. Thompson, C. Grant, M. Richards, T.J. Sebo, M. Rivera, V. Suman, S.M. Jenkins, R.C. Smallridge, K.C. Biblke, Survival in response to multimodal therapy in anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 102, 4506\u20134514 (2017)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3295_CR33","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1530\/EJE-16-0574","volume":"175","author":"J Wendler","year":"2016","unstructured":"J. Wendler, M. Kroiss, K. Gast, M.C. Kreissl, S. Allelein, U. Lichtenauer, R. Blaser, C. Spitzweg, M. Fassnacht, M. Schott, D. Fuhrer, V. Tiedje, Clinical presentation, treatment, and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Eur. J. Endocrinol. 175, 521\u2013529 (2016)","journal-title":"Eur. J. Endocrinol."},{"key":"3295_CR34","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1245\/ASO.2006.05.042","volume":"13","author":"C Are","year":"2006","unstructured":"C. Are, A.R. Shaha, Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann. Surg. Oncol. 13, 453\u2013464 (2006)","journal-title":"Ann. Surg. Oncol."},{"key":"3295_CR35","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"A. Maniakas, R. Dadu, N.L. Busaidy, J.R. Wang, R. Ferrarotto, C. Lu, M.D. Williams, G.B. Gunn, M.C. Hofmann, G. Cote, J. Seprling, N.D. Gross, E.M. Sturgis, R.P. Goepfert, S.Y. Lai, M.E. Cabanillas, M. Zafereo, Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncol. 6, 1397\u20131404 (2020)","journal-title":"JAMA Oncol."},{"key":"3295_CR36","doi-asserted-by":"publisher","first-page":"e2346","DOI":"10.1210\/clinem\/dgaa246","volume":"105","author":"NM I\u00f1iguez-Ariza","year":"2020","unstructured":"N.M. I\u00f1iguez-Ariza, S. Jasim, M.M. Ryder, A.V. Chintakuntlawar, J.C. Morris, C.R. Hilger, M.E. Menefee, R.C. Smallridge, N.J. Karlin, C. Alcaino, K.C. Bible, Foundation one genomic interrogation of thyroid cancers in patients with metastatic disease requiring systemic therapy. J. Clin. Endocrinol. Metab. 105, e2346\u2013e2357 (2020)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3295_CR37","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1089\/thy.2019.0133","volume":"29","author":"JR Wang","year":"2019","unstructured":"J.R. Wang, M.E. Zafereo, R. Dadu, R. Ferrarotto, N.L. Busaidy, C. Lu, S. Ahmed, M.K. Gule-Monroe, M.D. Williams, E.M. Sturgis, R.P. Goepfert, N.D. Gross, S.Y. Lai, G.B. Gunn, J. Phan, D.I. Rosenthal, C.D. Fuller, W.H. Morrison, P. Iyer, M.E. Cabanillas, Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF V600E\u2010mutated anaplastic thyroid carcinoma. Thyroid 29, 1036\u20131043 (2019)","journal-title":"Thyroid"},{"key":"3295_CR38","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"L.J. Wirth, E. Sherman, B. Robinson, B. Solomon, H. Hang, J. Lorch, F. Worden, M. Brose, J. Patel, S. Leboulleux, Y. Godbert, F. Barlesi, J.C. Morris, T.K. Owonikoko, D.S.W. Tan, O. Gautschi, J. Weiss, C. de la Fouchardiere, M.E. Burkard, J. Laskin, M.H. Taylor, M. Kroiss, J. Medioni, J.W. Goldman, T.M. Bauer, B. Levy, V.W. Zhu, N. Lakhani, V. Moreno, K. Evata, M. Nguyen, D. Heirich, E.Y. Zhu, X. Huang, L. Yang, J. Kherani, S.M. Rothenberg, A. Drilon, V. Subbiah, M.H. Shah, M.E. Cabanillas, Efficacy of Selpercatinib in RET-altered thyroid cancers. N. Engl. J. Med 383, 825\u2013835 (2020)","journal-title":"N. Engl. J. Med"},{"key":"3295_CR39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"2","author":"DS Hong","year":"2020","unstructured":"D.S. Hong, S.G. DuBois, S. Kummar, A.F. Farago, C.M. Albert, K.S. Rohrberg, C.M. van Tilburg, R. Nagasubramanian, J.D. Berlin, N. Federman, L. Mascarenhas, B. Geoerger, A. Dowlati, A.S. Pappo, S. Bielack, F. Doz, R. McDermott, J.D. Patel, R.J. Schilder, M. Tahara, S.M. Pfister, O. Witt, M. Ladanyi, E.R. Rudzinski, S. Nanda, B.H. Childs, T.W. Laetsch, D.M. Hyman, A. Drilon, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2, 531\u2013540 (2020)","journal-title":"Lancet Oncol."},{"key":"3295_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"V. Subbiah, R.J. Kreitman, Z.A. Wainberg, J.Y. Cho, J.H.M. Schellens, J.C. Soria, P.Y. Wen, C.C. Zielinski, M.E. Cabanillas, A. Boran, P. Ilankumaran, P. Burgess, T. Romero Salas, B. Keam, Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann. Oncol. 33, 406\u2013415 (2022)","journal-title":"Ann. Oncol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03295-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03295-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03295-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:03:22Z","timestamp":1744196602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03295-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["3295"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03295-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2169485\/v1","asserted-by":"object"}]},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"15 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors affirm that human research participants provided informed consent for the publication on the images in Figure(s) 1, 2, 3, and 4.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Written informed consent was obtained from the parents.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This is an observational study. The Research Ethics Committee has confirmed that no ethical approval is required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}